University of Illinois at Chicago
Announcement of an Exempt Purchase
Awarded to:Vendor: Cardinal Health, Dublin, OH
Amount: An estimated $1,250,000
Terms:
An estimated start date of 7/1/2020 through 6/30/2025
Renewals:
None
The University award process may be delayed up to thirty days as this award goes through a state approval process.
First published Friday, June 26, 2020
The University awarded a contract for Ra 223 (Xofigo).
The drug radium Ra 223 (Xofigo) is for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastases. Algeta is the sole manufacture of Ra 223 (Xofigo) and Cardinal is the sole distributor in the United States.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) This drug is needed to treat cancer patients. Currently Ra 223 is the only isotope available for treatment of patients with castration-resistant prostate cancer.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire
qualified veterans, minorities, females, persons with disabilities and ex-offenders.
